Nemucore Medical Innovations, Inc.
Developing life saving Precision Medicines for the treatment of Acute Myeloid Leukemia & Ovarian Cancer. Leveraging >$37M in non-dilutive product funding.
Nemucore Medical Innovations, Inc. is dedicated to the development and commercialization of Precision Medicines for the treatment of highly lethal cancers, particularly Acute Myeloid Leukemia (AML), Myelodysplastic syndromes (MDS) as well as ovarian, breast, and lung cancer.
Our lead product NMI-900 and its companion diagnostic are ready to enter clinical trials for AML and MDS at Memorial Sloan-Kettering and Moffitt Cancer Centers.